124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
11 clinical trials, 13 drugs (DrugBank: 4 drugs), 3 drug target genes, 11 drug target pathways
Searched query = "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", "CADASIL", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04334408 (ClinicalTrials.gov) | January 2021 | 2/4/2020 | Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL | A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL | Cadasil;Migraine | Drug: Fremanezumab;Drug: Placebo | Mayo Clinic | NULL | Not yet recruiting | 18 Years | 70 Years | All | 5 | Phase 2 | United States |
| 2 | NCT04658823 (ClinicalTrials.gov) | December 10, 2020 | 29/11/2020 | Efficacy and Safety of Tocotrienols in CADASIL | A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) | Cadasil | Drug: HOV-12020 (Palm tocotrienols complex);Drug: Placebo | Hovid Berhad | NULL | Not yet recruiting | 45 Years | 75 Years | All | 50 | Phase 2 | France |
| 3 | NCT01361763 (ClinicalTrials.gov) | June 2011 | 16/5/2011 | Safety Study of Dabigatran in CADASIL | Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL | CADASIL | Drug: Dabigatran;Drug: Antiplatelets | S. Andrea Hospital | NULL | Recruiting | 18 Years | N/A | Both | 50 | Phase 2 | Italy |
| 4 | EUCTR2007-004370-55-IT (EUCTR) | 14/12/2007 | 11/12/2007 | Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4 | Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4 | CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulthood and leading in some to severe motor disability with pseudobulbar palsy and dementia of the subcortical type MedDRA version: 9.1;Level: HLGT;Classification code 10008804;Term: Chromosomal abnormalities and abnormal gene carriers | Product Name: Phenoptin Product Code: 6R-BH4 INN or Proposed INN: sapropterin | AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE) | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
| 5 | EUCTR2004-001162-40-IT (EUCTR) | 05/04/2005 | 21/09/2005 | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. | Donezepil HCl for treatment of patients with CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy) who have cognitive impairment. MedDRA version: 6.1;Level: PT;Classification code 10009843 | Trade Name: ARICEPT 5*28 CPR 5 MG Product Name: NA Product Code: NA INN or Proposed INN: Donepezil | EISAI LTD UK | NULL | Not Recruiting | Female: yes Male: yes | Finland;United Kingdom;Germany;Spain;Italy;Sweden | ||||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2004-001162-40-SE (EUCTR) | 01/04/2005 | 03/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;United Kingdom;Germany;Spain;Italy;Sweden | |||
| 7 | EUCTR2004-001162-40-ES (EUCTR) | 29/03/2005 | 20/01/2006 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Finland;Spain;Germany;Italy;United Kingdom;Sweden | |||
| 8 | EUCTR2004-001162-40-FI (EUCTR) | 08/03/2005 | 28/12/2004 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
| 9 | EUCTR2004-001162-40-GB (EUCTR) | 24/02/2005 | 23/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Finland;Spain;Germany;Italy;United Kingdom;Sweden | |||
| 10 | NCT00103948 (ClinicalTrials.gov) | February 2005 | 17/2/2005 | The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment | Cognitive Impairment | Drug: Aricept | Eisai Limited | NULL | Completed | 25 Years | 70 Years | Both | 165 | Phase 2 | United States;Australia;Spain;Canada;Finland;France;Germany;Italy;Sweden;Switzerland;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2004-001162-40-DE (EUCTR) | 25/01/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;Spain;Germany;Italy;United Kingdom;Sweden |